Sign up Australia
Proactive Investors - Run By Investors For Investors

Actinogen Medical in an ASX trading halt

Actinogen Medical (ASX:ACW) has been granted a trading halt by the ASX, with its shares placed in pre-open.
Actinogen Medical in an ASX trading halt
Actinogen has been granted a trading halt.

Actinogen requested the halt pending details regarding Actinogen Medical’s application to the FDA to initiate its XanADu Phase II clinical trial in the US of Xanamem in the treatment of Alzheimer’s disease.

The halt will remain in place until the opening of trade on Wednesday 4th January 2017, or earlier if an announcement is made to the market.

View full ACW profile View Profile

Actinogen Medical Ltd Timeline

Related Articles

picture of doctor
September 06 2017
A Phase I clinical trial is to start later this year for the LOXL-2 inhibitor
Cancer highlighted
July 10 2017
The collaboration will see PDS Biotechnology Corp and a subsidiary of Merck & Co Inc embark on a new clinical trial collaboration for metastatic head and neck cancer
May 03 2017
The hybrid pharma services and drug development group has hit some key milestones over this year as trial results are eyed.

© Proactive Investors 2017

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use